trifluridine–tipiracil
Lonsurf
Pharmaceutical company: Taiho Oncology
NEW INDICATION & DOSAGE
Metastatic colorectal cancer in patients previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy and, if RAS wild-type, an anti-EGFR therapy in combination with bevacizumab
Adults: 35 mg/m2 PO b.i.d. up to a maximum of 80 mg/dose (based on trifluridine component) on days 1 through 5 and days 8 through 12 of a 28-day cycle. Round doses to nearest 5-mg increment. Continue until disease progression or unacceptable toxicity occurs. Refer to bevacizumab prescribing information for additional information.
Adjust-a-dose (for all indications): Refer to the manufacturer's instructions for dosage adjustments for kidney failure and hematologic and nonhematologic toxicities.
Released: October 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer
valbenazine
Ingrezza
Pharmaceutical company: Neurocrine Biosciences
NEW INDICATION & DOSAGE
Chorea associated with Huntington disease
Adults: Initially, 40 mg PO once daily. Increase dose in 20-mg increments every 2 weeks to the recommended dosage of 80 mg once daily. Some patients, 40 to 60 mg once daily may be appropriate based on response and tolerability.
Adjust-a-dose: For patients with Child-Pugh class B or C liver impairment, for those who are known poor metabolizers of CYP2D6, or if the drug is administered with a strong CYP2D6 or CYP3A4 inhibitor, give 40 mg once daily.
Boxed Warning: This drug increases the risk of depression and suicidality in patients with Huntington disease. Risks should be balanced with the clinical need for treatment when considering use. Use cautiously in patients with a history of depression or prior suicide attempts or suicidality. Monitor patients with Huntington disease for emergence or worsening of depression, suicidality, or unusual changes in behavior.
Released: October 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer